Combining therapies to improve treatment for endometrial cancer
Combination Therapies Targeting Insulin Signaling in Endometrial Cancer
This study is looking at how mixing different treatments can help improve care for women with endometrial cancer, especially those who are overweight, by focusing on how insulin affects cancer growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11138080 on NIH RePORTER |
What this research studies
This research investigates how combining different therapies can enhance the effectiveness of treatments for endometrial cancer, particularly in patients with obesity. It focuses on the role of insulin signaling in cancer progression and aims to lower insulin levels to improve the response to existing cancer therapies. The approach includes using patient-derived tumor tissues and animal models to test the effectiveness of these combined treatments. By understanding how insulin affects tumor growth, the research seeks to develop better treatment strategies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with endometrial cancer, especially those who are obese or have high insulin levels.
Not a fit: Patients with endometrial cancer who are not obese or do not have insulin-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with endometrial cancer, particularly those affected by obesity.
How similar studies have performed: Previous research has shown that targeting insulin signaling can improve cancer treatment outcomes, suggesting this approach may be promising.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Goncalves, Marcus Dasilva — New York University School of Medicine
- Study coordinator: Goncalves, Marcus Dasilva
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.